Continuous Low-Dose versus Standard-Dose Capecitabine Monotherapy as Second/Third-Line Chemotherapy for Metastatic Gastrointestinal Malignancies: A Retrospective Multicenter Analysis

2025-12-15 oncology Title + abstract only

Show abstract

BackgroundCapecitabine monotherapy is frequently employed as second/third-line treatment for metastatic gastrointestinal malignancies. Standard dosing often produces severe toxicities incompatible with palliative care principles. This study compared continuous low-dose (CLD) versus standard-dose (StD) capecitabine in the palliative setting. MethodsAfter at least one prior line of chemotherapy, 33 and 45 patients received StD (1.0-1.25 g/m2 bid on days 1-14 of a 21-day cycle) and CLD (500 mg bid...